Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk).
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Rising Debt CAPR has strong near-term liquidity and trades near tangible book value, but persistent losses, heavy cash burn, rising debt, and reliance on equity financing make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Recovery intact ⢠Volatile consolidation ⢠Breakout needed Support Level: $8.30â$8.60 Resistance Level: $9.40â$10.10 CAPR remains constructive above $8.30â$8.60 but needs a decisive break over $10.10 to resume upside amid volatile, weak-to-neutral momentum.
Sentiment & News
Key News Insights: ⢠FDA Disclosure Concerns ⢠Sharp Share Decline ⢠Investor Litigation Capricor faces significant downside risk as FDA disclosure concerns triggered a steep selloff and expanding shareholder litigation.
AI Summary
CAPR is now a high-risk regulatory-credibility trade: Deramiocel's upside depends less on clinical promise than on transparent evidence and FDA acceptance of protocol and blinding practices, so investors should await clear regulatory validation before treating the cash-backed valuation as a durable floor.
Description
Capricor Therapeutics is a clinical-stage biotechnology company developing cell- and exosome-based therapies for a range of diseases. Its lead candidate, CAP-1002, has completed a Phase III trial in late-stage Duchenne muscular dystrophy and is in Phase II testing for SARSâCoVâ2ârelated cytokine storm; the pipeline also includes a preclinical program for trauma-related injuries and vaccine candidates targeting COVIDâ19. The company outsources clinical manufacturing of CAP-1002 to Lonza Houston, was founded in 2005, and is based in San Diego, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 10 | Mar 17 | CAPR | Capricor Therapeutics, Inc. | High-risk regulatory/event play: FDA has resumed review of Capricor's BLA for Deramiocel after a Class 2 resubmission (PDUFA 2026-08-22), and management has flagged an imminent HOPEâ3 top-line readout. The stock rallied ~24% over 21 days on this setup; with clear dated catalysts and recent institutional interest, trading into/around the HOPEâ3 data window offers asymmetric near-term upside (balanced by binary trial and financing risk). | Closed | -6.6% |